Cytogenetic Response to Dasatinib Predictive for Progression-Free Survival in Imatinib-Resistant/Intolerant CML Patients

Capsule Summary CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting* Cytogenetic Response to Dasatinib Predictive for Progression-Free Survival in Imatinib-Resistant/Intolerant CML Patients Posting Date: December 12, 2008 Analysis[1] of pooled data from 2 phase II clinical trials: SRC-ABL Tyrosine Kinase Inhibition Activity Research Trial (START)–C and START-R Summary of Key Conclusions Cytogenetic responses rapidly attained with dasatinib 70 mg twice daily in imatinib-resistant/intolerant patients with chronic-phase chronic myeloid leukemia (CML) 89% of all complete cytogenetic responses achieved within first 12 months of treatment 47% of responses achieved within first 3 months of treatment Cytogenetic responses highly durable with dasatinib therapy 91% of complete cytogenetic responses maintained during 24 months of follow-up Achieving both major cytogenetic response and complete cytogenetic response at 12 months highly predictive for PFS ....read more